Medivir AB (Sweden) Performance
| MVIR Stock | 1.91 0.02 1.06% |
The company secures a Beta (Market Risk) of 0.41, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Medivir AB's returns are expected to increase less than the market. However, during the bear market, the loss of holding Medivir AB is expected to be smaller as well. At this point, Medivir AB has a negative expected return of -0.64%. Please make sure to verify Medivir AB's coefficient of variation, information ratio, total risk alpha, as well as the relationship between the standard deviation and jensen alpha , to decide if Medivir AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Medivir AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Medivir |
Medivir AB Relative Risk vs. Return Landscape
If you would invest 287.00 in Medivir AB on November 29, 2024 and sell it today you would lose (96.00) from holding Medivir AB or give up 33.45% of portfolio value over 90 days. Medivir AB is generating negative expected returns and assumes 3.5643% volatility on return distribution over the 90 days horizon. Simply put, 31% of stocks are less volatile than Medivir, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medivir AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medivir AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medivir AB, and traders can use it to determine the average amount a Medivir AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1788
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MVIR |
Estimated Market Risk
| 3.56 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.64 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medivir AB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medivir AB by adding Medivir AB to a well-diversified portfolio.
Things to note about Medivir AB performance evaluation
Checking the ongoing alerts about Medivir AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medivir AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medivir AB generated a negative expected return over the last 90 days | |
| Medivir AB may become a speculative penny stock | |
| Medivir AB has high historical volatility and very poor performance |
- Analyzing Medivir AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medivir AB's stock is overvalued or undervalued compared to its peers.
- Examining Medivir AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medivir AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medivir AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medivir AB's stock. These opinions can provide insight into Medivir AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Medivir Stock Analysis
When running Medivir AB's price analysis, check to measure Medivir AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medivir AB is operating at the current time. Most of Medivir AB's value examination focuses on studying past and present price action to predict the probability of Medivir AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medivir AB's price. Additionally, you may evaluate how the addition of Medivir AB to your portfolios can decrease your overall portfolio volatility.